Marinus Pharmaceuticals Inc

NASDAQ:MRNS  
5.34
-0.02 (-0.37%)
Products

Marinus Pharmaceuticals Announces FDA Approval Of Ztalmy (Ganaxolone) For Cdkl5 Deficiency Disorder

Published: 03/18/2022 18:37 GMT
Marinus Pharmaceuticals Inc (MRNS) - Marinus Pharmaceuticals Announces FDA Approval of Ztalmy® (ganaxolone) for Cdkl5 Deficiency Disorder.
Marinus Pharmaceuticals Inc - Ztalmy Significantly Reduced Major Motor Seizure Frequency in Cdd Patients in Pivotal Marigold Trial.
Marinus Pharmaceuticals Inc - Rare Pediatric Disease Priority Review Voucher Awarded to Marinus Pharmaceuticals by FDA.
Marinus Pharmaceuticals Inc - Ztalmy is Expected to Be Available Through a Designated Specialty Pharmacy in July 2022.